Accuray Announces First Patient Treatments in New Zealand With the CyberKnife® System, the World's Only Robotic Radiation Therapy Delivery Device
Auckland Radiation Oncology Selected the Latest-Generation CyberKnife S7™ System to Deliver Precise Treatments More Quickly, so Patients Can Rapidly Return to the Activities They Enjoy
"These first-in-country patient treatments reinforce the value the CyberKnife System provides to medical care teams around the globe. The addition of the Auckland Radiation Oncology center to the network of facilities using the CyberKnife System will broaden access to a trusted radiation therapy treatment option," said
The CyberKnife S7 System combines speed, precision and motion synchronization technology for the treatment of lesions and tumors throughout the body. Treatment is non-surgical, non-invasive and does not require incisions or general anesthesia. Clinical studies support the use of the CyberKnife System, expanding medical care team options for achieving outstanding outcomes for a wide range of indications.
ARO Clinical Director Dr.
"For example, instead of up to 20 rounds of radiation over four weeks for prostate cancer, with the CyberKnife, patients will likely only need one week of highly targeted treatment. This could be game changing for
Click here to learn more about the CyberKnife S7 System at Auckland Radiation Oncology.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.
About Auckland Radiation Oncology
Auckland Radiation Oncology is a joint venture, owned and operated by MercyAscot and
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace; and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Public Relations Director, Accuray
+1 (408) 789-4426
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-first-patient-treatments-in-new-zealand-with-the-cyberknife-system-the-worlds-only-robotic-radiation-therapy-delivery-device-301722612.html